Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 3,757 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Cardiovascular Diseases, Cardiac Rehabilitation
Interventions: Text Messaging, Fully Automated Online Program, Low-Intensity Cardiac Rehabilitation Maintenance Program, High Intensity Cardiac Rehabilitation Maintenance Program; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more

Conditions: Breast Neoplasms
Interventions: PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more

Conditions: Multiple Myeloma
Interventions: Radiation; Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Major Depressive Disorder
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Endometrial Cancer, Endometrial Carcinoma, Neoplasms, Endometrial
Interventions: MK-3475, Surgical resection (standard of care), Paclitaxel (standard of care), Carboplatin (standard of care), Radiation (standard of care), Endometrial biopsy, Peripheral blood draw; Drug · Procedure · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Latanoprost, Arm 2, Latanoprost SR insert; Drug
Lead sponsor: Daniel Moore; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions: Angiomax (bivalirudin); Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hippel-Lindau Disease, Kidney Cancer
Interventions: 17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: Talimogene laherparepvec, Ipilimumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions: Instilled T3, Placebo Therapy; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
Interventions: AG-01 Compound; Drug
Lead sponsor: A&G Pharmaceutical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post Concussion Symptoms
Interventions: Concussion Questionnaire; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Keloid
Interventions: RXI-109, Placebo; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: Traumatic Brain Injury
Interventions: Premarin IV, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, LUMIGAN; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more

Conditions: Contraception
Interventions: Norgestrel 0.075 mg tablets; Drug
Lead sponsor: HRA Pharma; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Homewood, Alabama • McCalla, Alabama + 38 more

Conditions: Hemodialysis Access
Interventions: Vascugel, Placebo Comparator; Biological
Lead sponsor: Pervasis Therapeutics, Inc; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye, Neurotrophic Keratitis
Interventions: Cenegermin Ophthalmic Solution [Oxervate]; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Drug Dependence, Substance Use Disorders
Interventions: Recovery Line; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine, Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed, Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel, Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Osteoarthritis, Osteo Arthritis Knee
Interventions: Colchicine 0.8 mg or 0.6 mg orally once daily, Placebo oral capsule; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: N-Acetylcysteine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

SMART to Optimize an Intervention to Maintain Health Improvements After Cardiac Rehabilitation

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Hypofractionation (Radiation) Trial for Multiple Myeloma

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

MK-3475 Immunotherapy in Endometrial Carcinoma

Safety Study of Latanoprost Slow Release Insert

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Effects of Anesthesia on Pediatric Surgical Patients With a History of Concussion - Phase I

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Study of Oral Contraception Under Simulated OTC Conditions

Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use

DOMPE -MT Neurotrophic Keratitis

Automated Recovery Line for Medication Assisted Treatment

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

Colchicine for the Treatment of Osteoarthritis of the Knee

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma